Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
To date, evidence for long-term renoprotection with angiotensin receptor blockers (ARBs) has come almost exclusively from Caucasian patients (1–3), despite Japanese people being at high risk of diabetic nephropathy and very susceptible to end-stage renal disease (4–6). We conducted the INNOVATION Study (Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy) to evaluate the efficacy of an ARB in preventing transition from microalbuminuria to overt nephropathy in Japanese patients (7). This study is the first large-scale clinical study to investigate prevention of overt diabetic nephropathy using an ARB in normotensive and hypertensive Japanese patients with type 2 diabetes. The randomized, multicenter, double-blind, placebo-controlled trial was performed in patients aged from 30 to 74 years with type 2 diabetes and urinary albumin-to-creatinine ratio (UACR) 100–300 mg/g and serum creatinine <1.5 mg/dl (men) and <1.3 mg/dl (women). Exclusion criteria included type 1 diabetes, age of diabetes onset <30 years, seated systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥180/100 mmHg, and definable chronic kidney disease …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, telmisartan also signi fi cantly reduced blood pressure levels.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“In the INNOVATION trial, the ARB telmisartan was associated with a lower transition rate to overt nephropathy than placebo after 1 year of follow-up.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“suggesting that use of RAS blockade may be bene fi cial in patients without hypertension. 12,14”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“However, after adjustment for the difference in blood pressure levels between the placebo and treatment groups, the bene fi cial effect of telmisartan in delaying progression to overt nephropathy persisted.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“The CREDENCE, DAPA-CKD, and EMPA-KIDNEY placebo-controlled trials were all stopped early for efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, respectively.153,543,711”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [711]
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Progression, remission, regression of chronic renal diseases
Ruggenenti, P., Schieppati, A., & Remuzzi, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04728-0 · Cited by 554
An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001)1
Patient Registration Committee, J. S. F. D. T. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00109.x · Cited by 68
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300610 · Cited by 32
Self-citationHollenberg, N. K. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0035-5 · Cited by 8
Cited by
Items 101–200 of 228
Inoue, A., Babazono, T., & Iwamoto, Y. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2007.53 · Cited by 19
Self-citationUzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164936 · Cited by 18
Self-citationChronic Kidney Disease Stages 1–3
Ha, F., Ishani, A., Taylor, B. C., Nl, G., MacDonald, R. H., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012) · Europe PMC (PubMed Central) · Cited by 18
Chronic Kidney Disease in Japan from Early Predictions to Current Facts
Iseki, K. (2008) · Nephron Clinical Practice · doi:10.1159/000170094 · Cited by 18
Kawazoe, H., Yano, A., Ishida, Y., Takechi, K., Katayama, H., Ito, R., Yakushijin, Y., Moriguchi, T., Tanaka, M., Tanaka, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171066 · Cited by 18
Cao, Z., & Cooper, M. E. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0328-3 · Cited by 20
Abdelkader, N. N., Awaisu, A., Elewa, H. F., & Hajj, M. S. E. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100315 · Cited by 24
Ishibashi, T., Morita, S., Furuta, H., Nishi, M., & Matsuoka, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-43614-9 · Cited by 22
Shima, A., Miyamoto, M., Kubota, Y., Takagi, G., & Shimizu, W. (2015) · Journal of Nippon Medical School · doi:10.1272/jnms.82.84 · Cited by 17
Coleman, C. I., Weeda, E. R., Kharat, A. A., Bookhart, B., & Baker, W. L. (2019) · Diabetic Medicine · doi:10.1111/dme.14107 · Cited by 17
Telmisartan and cardioprotection
McFarlane, S. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9447 · Cited by 26
Telmisartan: A Review of its Use in Cardiovascular Disease Prevention
Frampton, J. E. (2011) · Drugs · doi:10.2165/11206710-000000000-00000 · Cited by 17
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Therapeutic management of diabetic kidney disease
Koya, D., Araki, S., & Haneda, M. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00112.x · Cited by 17
Self-citationFrancischetti, E. A., Celoria, B. M. J., Francischetti, A., & Genelhu, V. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.289 · Cited by 18
Nakatani, S., Ishimura, E., Naganuma, T., Nakatani, A., Ichii, M., Fukumoto, S., Mori, K., Emoto, M., Nakatani, T., & Inaba, M. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.019 · Cited by 18
Therapeutic Insights against Oxidative Stress Induced Diabetic Nephropathy: A Review
Agarwal, N., & Sadhukhan, P. (2015) · Journal of Autoimmune Disorders · doi:10.21767/2471-8153.100002 · Cited by 14
Sourij, H., Aberer, F., Antlanger, M., Brix, J., Cejka, D., Clodi, M., Edlinger, R., Eller, K., Horn, S., Kaser, S., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0992-y · Cited by 14
Abdel-Wahab, A. F. (2016) · Nephrology & Renal Therapy · doi:10.24966/nrt-7313/100010 · Cited by 16
Yamamoto, R., Kanazawa, A., Shimizu, T., Hirose, T., Tanaka, Y., Kawamori, R., & Watada, H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.01.009 · Cited by 14
Self-citationTelmisartan as a metabolic sartan for targeting vascular failure
Inoue, T., & Node, K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1397 · Cited by 16
Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
Goldenberg, R., Berall, M. J., Chan, C. T., Cherney, D. Z. I., Lovshin, J. A., McFarlane, P. A., Senior, P. A., Verma, S., & Weinstein, J. J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.008 · Cited by 17
Kidney disease in diabetology: lessons from 2007
Schernthaner, G.-H. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn060 · Cited by 14
Wada, J., & Makino, H. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0175-5 · Cited by 11
Self-citationUshigome, E., Fukui, M., Hamaguchi, M., Tanaka, T., Atsuta, H., Ohnishi, M., Oda, Y., Yamazaki, M., Hasegawa, G., & Nakamura, N. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12052 · Cited by 13
Shikata, K., Haneda, M., Koya, D., Suzuki, Y., Tomino, Y., Yamada, K., Maeda, S., Kawakami, N., Uzu, T., Nishimura, M., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.025 · Cited by 14
Self-citationPostma, M. J., & de Zeeuw, D. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp352 · Cited by 16
Hypertension management in patients with chronic kidney disease
Palmer, B. F. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0069-z · Cited by 13
Weir, M. R. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.01.1958 · Cited by 13
Volpe, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.80 · Cited by 13
Investigational drugs for diabetic nephropathy
Cortinovis, M., Cattaneo, D., Perico, N., & Remuzzi, G. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1487 · Cited by 14
Mallat, S. G. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-108 · Cited by 15
Kröpelin, T. F., de Zeeuw, D., Remuzzi, G., Bilous, R., Parving, H., & Heerspink, H. J. L. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101150 · Cited by 10
Slowing the progression of kidney disease in patients with diabetes
Burgess, E. D. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2008.03.007 · Cited by 10
Tocci, G., & Volpe, M. (2011) · Drugs · doi:10.2165/11591350-000000000-00000 · Cited by 11
Tsuruta, H., Yasuda‒Yamahara, M., Yoshibayashi, M., Kuwagata, S., Yamahara, K., Tanaka‒Sasaki, Y., Chin‒Kanasaki, M., Matsumoto, S., Ema, M., & Kume, S. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167074 · Cited by 11
Berger, M., Marx, N., & Marx-Schütt, K. (2025) · European Cardiology Review · doi:10.15420/ecr.2024.29 · Cited by 15
Yoshihara, F., Imazu, M., Sakuma, I., Hiroi, Y., Hara, H., Okazaki, O., Ishiguro, C., Izumi, C., Noguchi, T., Shiraiwa, T., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102334 · Cited by 11
Self-citationTakihata, M., Nakamura, A., Kondo, Y., Kawasaki, S., Kimura, M., & Terauchi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125519 · Cited by 10
Review: The problem of diabetic nephropathy and practical prevention of its progression
Wright, J. R., & Vardhan, A. (2008) · The British Journal of Diabetes · doi:10.1177/1474651408099654 · Cited by 9
Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona
Egocheaga, M. I., Hernández, Y. D., & Otero, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102018 · Cited by 11
Alpert, M., Govindarajan, G., Rosario, M. L. D., & Reisin, E. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00035.x · Cited by 8
Blood pressure management in patients with type 2 diabetes mellitus
Kai, H. (2017) · Hypertension Research · doi:10.1038/hr.2017.55 · Cited by 8
An, J. N., Hwang, J. H., Lee, J. P., Chin, H. J., Kim, S., Kim, D. K., Kim, S., Park, J. H., Shin, S. J., Lee, S. H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128632 · Cited by 8
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Dimitriadis, K. S., Pyrpyris, N., Vakka, A., Iliakis, P., Theofilis, P., Tatakis, F., Beneki, E., Pitsiori, D., Tsioufis, P., Aznaouridis, K. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348953250310044927 · Cited by 11
Tan, S., Wong, L. Y., & Toh, M. P. H. (2018) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v47n12p502 · Cited by 7
Ogawa, S., Matsushima, M., Mori, T., Okamura, M., Senda, M., Sakamoto, T., Nako, K., & Ito, S. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt085 · Cited by 7
Self-citationKim‐Mitsuyama, S., Soejima, H., Yasuda, O., Node, K., Jinnouchi, H., Yamamoto, E., Sekigami, T., Ogawa, H., & Matsui, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-20874-4 · Cited by 7
Drug Dosing for Renoprotection
de Zeeuw, D., & Lambers-Heerspink, H. J. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009020172 · Cited by 7
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Telmisartan – an effective antihypertensive for 24-hour blood pressure control
Chambers, S. (2008) · Drugs in Context · doi:10.7573/dic.212220 · Cited by 6
Chung, S. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.6.270 · Cited by 8
Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies
Iqbal, S. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s9-006 · Cited by 7
Beneficial Effects of Telmisartan in an HIV+ Diabetic Insulin-Dependent Patient
Ucciferri, C., Mancino, P., Vecchiet, J., & Falasca, K. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200334 · Cited by 6
Association between equol producers and type 2 diabetes mellitus among Japanese older adults
Hamaura, K., Murakami, H., Tamura, A., Matsuki, K., Sato, E., Tanabe, J., Yanagimachi, M., Oishi, M., Iino, K., Okuyama, S., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13995 · Cited by 6
Fujii, M., Inaguma, D., Koide, S., Ito, E., Takahashi, K., Hayashi, H., Tsuboi, N., Hasegawa, M., & Yuzawa, Y. (2018) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12778 · Cited by 6
Ruilope, L. M., & Segura, J. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802279066 · Cited by 7
Burgess, E. D. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)71169-7 · Cited by 5
Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease: A Difficult Equation
Sanidas, E. A., Papadopoulos, D., Chatzis, M., Velliou, M., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00467-9 · Cited by 7
Kakio, Y., Uchida, H. A., Umebayashi, R., Takeuchi, H., Okuyama, Y., Hanayama, Y., & Wada, J. (2017) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000229 · Cited by 5
Telmisartan in High Cardiovascular Risk Patients
Asmar, R. G. (2012) · European Cardiology Review · doi:10.15420/ecr.2012.8.1.10 · Cited by 4
Main results and clinical interpretations from the TRANSCEND study
de la Sierra, A. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000354516.44580.ca · Cited by 4
Cardiac and vascular protection: the potential of ONTARGET.
Mancia, G., Jakobsen, A., Heroys, J., Ralph, A., Rees, T., & Shaw, M. (2008) · PubMed · Cited by 5
Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan
Unger, T. (2012) · ISRN Vascular Medicine · doi:10.5402/2012/712047 · Cited by 7
Parving, H., Mauer, M. S., Fioretto, P., Rossing, P. R., & Ritz, E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10038-7 · Cited by 10
Sawai, T., Dohi, K., Fujimoto, N., Okubo, S., Isaka, N., Ichikawa, T., Makino, K., Okamoto, S., Koyabu, S., Kitamura, T., et al. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13054 · Cited by 4
Kubota, M., Shiroyama, E., Tanaka, K., & Yoshii, Y. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00707-0 · Cited by 4
Zenteno-Castillo, P., Muñoz-López, D. B., Merino-Reyes, B., Vega-Sánchez, Á. E., Preciado‐Puga, M. D. C., González-Yebra, A. L., & Kornhauser, C. (2015) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2015.08.001 · Cited by 5
Nishiwaki, H., Niihata, K., Shimizu, S., Shibagaki, Y., Yamamoto, R., Nitta, K., Tsukamoto, T., Uchida, S., Takeda, A., Okada, H., et al. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14224 · Cited by 5
Zeng, X., Xing, Y.-H., Xiu-mei, M., Long, Y., Jiang, Z., & Xu, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319053 · Cited by 4
Nishihama, K., Nakai, T., Kanai, K., Sugiyama, T., Kosato, H., Oka, N., Yasutomi, M., Murata, K., Ohnishi, T., & Yabana, T. (2014) · CEN Case Reports · doi:10.1007/s13730-014-0150-1 · Cited by 3
In Vitro Study of the Juxtaglomerular Apparatus and Its Implications in the Chronic Kidney Disease
Ito, S. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04365 · Cited by 3
Self-citationImpact of telmisartan in modifying vascular risk
Baguet, J.-P., Ormezzano, O., & Barone-Rochette, G. (2010) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s6707 · Cited by 5
Diseases of Renal Microcirculation: Diabetic Nephropathy
Riphagen, I. J., Heerspink, H. J. L., Gans, R. O. B., & Gaillard, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_149-1 · Cited by 3
Kalaitzidis, R., & Bakris, G. L. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1979 · Cited by 6
Rodríguez-Pérez, J., Bello, M. Á. G., Anabitarte, A., Companioni, O., Nóvoa-Mogollón, F. J., Ortega, S. S., Plaza-Toledano, C., & Rodríguez‐Esparragón, F. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2011.561900 · Cited by 3
Sourij, H., Edlinger, R., Prischl, F. C., Auinger, M., Kaser, S., Horn, S., Paulweber, B., Kautzky‐Willer, A., Säemann, M. D., Prager, R., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1425-x · Cited by 3
Chapter 7. Hypertension complicated by other diseases
(2014) · Hypertension Research · doi:10.1038/hr.2014.10 · Cited by 4
Clinical studies on pharmacological treatment of hypertension in Japan
Kario, K., Hoshide, S., Yamamoto, K. I., Okura, A., & Rakugi, H. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00533-4 · Cited by 3
Chapter 5. Treatment with antihypertensive drugs
(2014) · Hypertension Research · doi:10.1038/hr.2014.8 · Cited by 6
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.62 · Cited by 3
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Telmisartan: clinical evidence across the cardiovascular and renal disease continuum
Patel, P. M. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0366-6 · Cited by 3
Target‐organ protection with combination renin‐angiotensin‐system blockade
PrisantMD, L. M. (2009) · Clinical Cardiology · doi:10.1002/clc.20337 · Cited by 3
ARB and the Slowing of Progression of Diabetic Nephropathy 2001
Buchbinder, S. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-25620-2_40 · Cited by 1
Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice
Weber, M. A. (2013) · Endocrine Practice · doi:10.4158/ep12361.or · Cited by 1
Neldam, S., & Guthrie, R. M. (2011) · Aging Health · doi:10.2217/ahe.11.9 · Cited by 1
Meschi, M., Esposti, E. D., Esposti, L. D., Spagnoli, F., Giuri, P. G., Fiaccadori, E., & Caiazza, A. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2013.433 · Cited by 1
Ivanov, D. D., & Ivanova, M. D. (2020) · KIDNEYS · doi:10.22141/2307-1257.9.3.2020.211461 · Cited by 2
Diseases of Renal Microcirculation: Diabetic Nephropathy
Riphagen, I. J., Heerspink, H. J. L., Gans, R. O. B., & Gaillard, S. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_149 · Cited by 1
Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes
Leung, A. A. C. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_24 · Cited by 2
Prophylaxe und Therapie der diabetischen Nephropathie
Kettner, C., & Mann, J. F. E. (2017) · Der Nephrologe · doi:10.1007/s11560-017-0193-3 · Cited by 1
Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease
Eng, E., & Quaggin, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_29 · Cited by 1
Shah, N., Perkovic, V., & Kotwal, S. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108402 · Cited by 3
Chazova, I. E., Zhernakova, Y. V., Звартау, Н. Э., Zagidullin, N. S., Ксенева, С. И., Trifonova, O. Y., & Erofeeva, S. B. E. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-2-17-26 · Cited by 1
Lessons in Hypertension from New Clinical Trials
Nesbitt, S. D. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2075 · Cited by 1
Qureshi, A. C. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique)
The Role of Renin Angiotensin System Inhibitors in Renal Protection: Lessons from Clinical Trials
Stojiljković, L. (2012) · InTech eBooks · doi:10.5772/25957
Kuriyama, S., Sugano, N., Takane, K., Kobayashi, A., Otsuka, Y., & Hosoya, T. (2013) · Open Journal of Nephrology · doi:10.4236/ojneph.2013.32015
Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan
Oikawa, Y., Shimada, A., & Kyo, M. (2013) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2013.35034
Metadata
- Authors
- Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group
- Affiliations
- Okayama University (JP)
- Asahikawa Medical University (JP)
- Tokyo Women's Medical University (JP)
- Kitasato University (JP)
- Tohoku University (JP)
- Juntendo University (JP)
- Saitama Medical University (JP)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1577-1578
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2140563977
- Cited by
- 230
- References
- 8
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 14 · 2022: 8 · 2021: 8 · 2020: 12 · 2019: 3 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 14 · 2014: 14 · 2013: 17 · 2012: 21
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- telmisartan, angiotensin receptor blockers, diabetic nephropathy, type 2 diabetes, microalbuminuria, renal protection, Japanese patients, hypertension, albumin-creatinine ratio
- MeSH terms
- Telmisartan, Adult, Aged, Albuminuria, Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Benzoates, Diabetic Nephropathies, Double-Blind Method, Humans, Middle Aged, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.